Retrospective study on drug interaction of tuberculosis and pulmonary Mycobacterium avium complex disease therapeutic drugs by using data of clinical symptoms and laboratory test results.
Not Applicable
- Conditions
- Tuberculosis and pulmonary Mycobacterium avium complex disease
- Registration Number
- JPRN-UMIN000010588
- Lead Sponsor
- aboratory of pharmacotherapeutics, Tokyo University of Science
- Brief Summary
Our study suggests that the combination of CAM and LVFX causes unfavorable clinical outcomes for pulmonary MAC disease treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
None.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Study on interaction with rifampicin and diabetes therapeutic drugs in tuberculosis patients: blood glucose and hemoglobin A1c level. 2) Study on interaction with rifampicin and clarithromycin in pulmonary Mycobacterium avium complex disease patients: clinical symptoms of subjects (cough, sputum and hemosputum etc. ), chest radiographic findings, examination of sputum (smear and culture) and clinical laboratory test results. 3) Study on interaction with clarithromycin and levofloxacin in pulmonary Mycobacterium avium complex disease patients: clinical outcome of subjects (smear and culture test).
- Secondary Outcome Measures
Name Time Method